Gilead Sees Plenty Of Room For Yescarta Adoption To Grow
An exec told the company’s Q3 earnings call it was “surprising” that cell therapy adoption for LBCL remains around only 10% of eligible patients despite Yescarta producing strong clinical data.
You may also be interested in...
The Swiss drug maker is licensing multiple DLL3-targeting CAR-Ts from the Chinese biotech, including one already in early clinical development, and will use its T-Charge manufacturing platform.
The drug maker announced early data for zimberelimab/domvanalimab in gastrointestinal cancers that it called encouraging, though an analyst was more skeptical due to limited interpretability.
The company presented results from the ZUMA-7 trial at ASCO for the CAR-T therapy in the curative setting of large B-cell lymphoma.